Sakar Healthcare
NSE: SAKAR · Pharmaceuticals
Snapshot
Unlock Sakar Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sakar Healthcare Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a diverse range of formulations. Its product portfolio spans 22 therapeutic areas, including liquid orals, tablets, capsules, and various injectable formats.
Business Model
The company generates revenue by manufacturing and selling pharmaceutical formulations across domestic and international markets. It serves a global footprint, exporting products to approximately 38 countries across regions including Southeast Asia, Africa, MENA, and the United States.
- Therapeutic Areas:22
- Export Markets:38 countries
Growth Outlook
Growth is driven by the expansion of its diverse product portfolio and the strengthening of its international presence in regulated and emerging markets. The company continues to leverage its manufacturing capabilities in lyophilized injections and other specialized dosage forms to capture global demand.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to export bans or product recalls.
- Foreign Exchange Volatility. As a significant exporter to 38 countries, the company is exposed to fluctuations in currency exchange rates which may impact profit margins.
- Pricing Pressure. The pharmaceutical sector is subject to intense price competition and government-mandated price controls on essential medicines in India and abroad.
- Supply Chain Disruptions. Dependence on the timely procurement of active pharmaceutical ingredients and raw materials makes the company vulnerable to global supply chain volatility.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Sakar Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹252 Cr
TTM · consolidated
NET PROFIT
₹30 Cr
TTM · consolidated
EPS
₹13.69
TTM · consolidated
RETURN ON EQUITY
10.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.3%
TTM · consolidated
P/E
65.5x
Q4 FY26 · consolidated
EV/EBITDA
28.4x
Q4 FY26 · consolidated
EBITDA MARGIN
28.3%
TTM · consolidated
NET PROFIT MARGIN
15.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sakar HealthcareSAKAR | 1,148 | 65.52 | 28.44 | 41.8% | 28.3% | 10.3% | 13.3% | +148.6% |
Lincoln Pharma.LINCOLN | 1,173 | 13.71 | 9.06 | 7.7% | 19.5% | 12.7% | 16.4% | +7.8% |
Ind-Swift Labs.INDSWFTLAB | 1,168 | 44.47 | 17.62 | 226.0% | 14.7% | 3.4% | 4.0% | +121.7% |
Venus RemediesVENUSREM | 1,157 | 23.25 | 14.80 | 18.0% | 20.9% | 17.5% | 22.1% | +239.7% |
Hester BiosHESTERBIO | 1,150 | 36.08 | 23.45 | 6.9% | 29.0% | 17.6% | 15.2% | +31.0% |
Beta Drugs LtdBETA | 1,096 | — | — | — | 20.0% | — | — | +34.8% |
As of Q4 FY26
Financials
Sakar Healthcare
NSE: SAKAR · Pharmaceuticals
Snapshot
Unlock Sakar Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sakar Healthcare Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a diverse range of formulations. Its product portfolio spans 22 therapeutic areas, including liquid orals, tablets, capsules, and various injectable formats.
Business Model
The company generates revenue by manufacturing and selling pharmaceutical formulations across domestic and international markets. It serves a global footprint, exporting products to approximately 38 countries across regions including Southeast Asia, Africa, MENA, and the United States.
- Therapeutic Areas:22
- Export Markets:38 countries
Growth Outlook
Growth is driven by the expansion of its diverse product portfolio and the strengthening of its international presence in regulated and emerging markets. The company continues to leverage its manufacturing capabilities in lyophilized injections and other specialized dosage forms to capture global demand.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where non-compliance could lead to export bans or product recalls.
- Foreign Exchange Volatility. As a significant exporter to 38 countries, the company is exposed to fluctuations in currency exchange rates which may impact profit margins.
- Pricing Pressure. The pharmaceutical sector is subject to intense price competition and government-mandated price controls on essential medicines in India and abroad.
- Supply Chain Disruptions. Dependence on the timely procurement of active pharmaceutical ingredients and raw materials makes the company vulnerable to global supply chain volatility.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Sakar Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹252 Cr
TTM · consolidated
NET PROFIT
₹30 Cr
TTM · consolidated
EPS
₹13.69
TTM · consolidated
RETURN ON EQUITY
10.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
13.3%
TTM · consolidated
P/E
65.5x
Q4 FY26 · consolidated
EV/EBITDA
28.4x
Q4 FY26 · consolidated
EBITDA MARGIN
28.3%
TTM · consolidated
NET PROFIT MARGIN
15.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26